nach oben

Erschienen in:

20.12.2019 | Herzrhythmusstörungen | Konsensuspapiere

Diagnostik und Therapie der kardialen Sarkoidose

Konsensuspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) und Deutschen Gesellschaft für Kardiologie – Herz und Kreislaufforschung (DGK)

verfasst von: D. Skowasch, F. Gaertner, N. Marx, B. Meder, J. Müller-Quernheim, M. Pfeifer, J. W. Schrickel, A. Yilmaz, Prof. Dr. med. C. Grohé

Erschienen in: Die Kardiologie | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Während 90 % aller Sarkoidosepatienten eine parenchymatöse Beteiligung der Lunge aufweisen, ist die kardiale Sarkoidose (in weniger als 10 % der Fälle klinisch manifest) selten. Generell können alle Strukturen des Herzens von der Granulombildung betroffen sein. Meist jedoch sind das Myokard des linken Ventrikels sowie das Reizleitungssystem beeinträchtigt. Klinisch manifestiert sich die kardiale Sarkoidose als dilatative Kardiomyopathie oder in Form von Herzrhythmusstörungen wie Vorhofflimmern und/oder ventrikulären Tachykardien. Das Spektrum reicht von der benignen, subklinischen Manifestation als Zufallsbefund bis zur lebensbedrohlichen Komplikation, wie aktuelle Kohortenstudien zeigen. Diagnostische Schritte und therapeutische Empfehlungen zur kardialen Sarkoidose sollten daher einem einheitlichen Standard unterliegen. Die vorliegende Arbeit ist die Expertenstellungnahme unter dem Schirm der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) und der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK). Die nachstehenden Empfehlungen ersetzen jedoch nicht die ärztliche Begutachtung des individuellen Patienten und Anpassung der Diagnostik und Therapie an dessen spezifische Situation.

Costabel U, Skowasch D, Pabst S et al (2014) Diagnostik und Therapie der kardialen Sarkoidose. Pneumologie 68:124–132PubMed

Hiraga H, Hiroe M, Iwai K (1993) Guideline for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary diseases (in Japanese). The Japanese Ministry of Health and Welfare, Tokyo, S 23–24

Kitaichi M, Shigemitsu H, Nagai S (2007) Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 27:89–102

Birnie DHDH, Nery PB, Ha AC, Beanlands RS (2016) Cardiac Sarcoidosis. J Am Coll Cardiol 68(4):411–421PubMed

Slart RHJA, Glaudemans AWJM, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, Jaber WA, Russell R, Gimelli A, Rouzet F, Hacker M, Gheysens O, Plein S, Miller EJ, Dorbala S, Donal E, Document Reading Group (2018) A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol 25(1):298PubMed

Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, Birnie DH, Chen ES, Cooper LT, Tung RH, White ES, Borges-Neto S, Di Carli MF, Gropler RJ, Ruddy TD, Schindler TH, Blankstein R, NAME OF COLLAB GROUP (2017) Joint SNMMI-ASNC Expert Consensus Document on the Role of ₁₈F‑FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. J Nucl Med 58(8):1341PubMedPubMedCentral

Pabst S, Skowasch D, Grohé C (2012) Sarkoidose. Pneumologie 66:96–109PubMed

Pabst S, Tuleta I, Grohé C (2008) Kardiale Sarkoidose. Kardiologe 2:299–311

Pietinalho A, Hiraga Y, Hosoda Y, Löfroos AB, Yamaguchi M, Selroos O (1995) The frequency of sarcoidosis in Finland and Hokkaido, Japan: a comparative epidemiological study. Sarcoidosis 12:61–67PubMed

10.

Jamilloux Y, Maucort-Boulch D, Kerever S, Gerfaud-Valentin M, Broussolle C, Eb M, Valeyre D, Seve P (2016) Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J 48(6):1700–1709PubMed

11.

Deubelbeiss U, Gemperli A, Schindler C, Baty F, Brutsche MH (2010) Prevalence of sarcoidosis in Switzerland is associated with environmental factors. Eur Respir J 35:1088–1097PubMed

12.

Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, Kaikkonen K, Tuohinen S, Haataja P, Kerola T, Kokkonen J, Pelkonen M, Pietila-Effati P, Utrianen S, Kupari M (2015) Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 131(7):624–632PubMed

13.

Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J (2016) Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 48(6):1690–1699PubMed

14.

Vita T, Okada DR, Veillet-Chowdhury M, Bravo PE, Mullins E, Hulten E, Agrawal M, Madan R, Taqueti VR, Steigner M, Skali H, Kwong RY, Stewart GC, Dorbala S, Di Carli MF, Blankstein R (2018) Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging 11:e7030PubMedPubMedCentral

15.

Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145:234–241PubMed

16.

Schupp JC, Freitag-Wolf S, Bargagli E, Mihailovic-Vucinic V, Rottoli P, Grubanovic A, Muller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O’Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Gunther A, Weihrich A, Petrek M, Kolek V, Keane MP, O’Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peros-Golubicic T, Luisetti M, Kadija Z, Pabst S, Grohe C, Strausz J, Vasakova M, Sterclova M, Millar A, Homolka J, Slovakova A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Muller-Quernheim J (2018) Phenotypes of organ involvement in sarcoidosis. Eur Respir J. https://doi.org/10.1183/13993003.00991-2017 CrossRef

17.

Youssef G, Beanlands RSB, Birnie DH, Nery PB (2011) Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 97:2078–2087PubMed

18.

Smedema JP, Snoep G, van Kroonenburgh MP et al (2005) Cardiac involvement in patients with pulmonary sarcoidosis at two university medical centers in the Netherlands. Chest 128:30–35PubMed

19.

Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J (2014) Sarcoidosis. Lancet 383(9923):1155–1167PubMed

20.

Guo X, Vittinghoff E, Vedantham V, Pletcher MJ, Lee BK (2017) Trends in hospitalizations for cardiac Sarcoidosis in the United States, 2005–2011. Circ J 81(11):1739–1741PubMed

21.

Yazaki Y, Isobe M, Hiroe M et al (2001) Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88:1006–1010PubMed

22.

Shigemitsu H, Nagai S, Sharma OP (2007) Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med 13:434–438PubMed

23.

Kandolin R, Lehtonen J, Graner M et al (2011) Diagnosing isolated cardiac sarcoidosis. J Intern Med 270:461–468PubMed

24.

Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML (2005) Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 128:1483–1489PubMed

25.

Handa T, Nagai S, Miki S et al (2006) Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129:1246–1252PubMed

26.

Bourbonnais JM, Samavati L (2008) Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 32:296–302PubMed

27.

Baughman RP, Engel PJ, Taylor L, Lower EE (2010) Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 138:1078–1085PubMed

28.

Nunes H, Humbert M, Capron F et al (2006) Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 61:68–74PubMed

29.

Shlobin OA, Nathan SD (2012) Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 39:1520–1533PubMed

30.

Simmonneau G, Montani D, Celermajer DS et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53:1801913

31.

Pabst S, Hammerstingl C, Grau N, Kreuz J, Grohe C, Juergens UR, Nickenig G, Skowasch D (2013) Pulmonary arterial hypertension in patients with sarcoidosis: the pulsar single center experience. Adv Exp Med Biol 755:299–305PubMed

32.

Murtagh G, Laffin LJ, Patel KV, Patel AV, Bonham CA, Yu Z, Addetia K, El-Hangouche N, Maffesanti F, Mor-Avi V, Hogarth DK, Sweiss NJ, Beshai JF, Lang RM, Patel AR et al (2016) Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction. Circ Cardiovasc Imaging 9:e3738PubMedPubMedCentral

33.

Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S, Bittencourt MS, Murthy VL, Kwong R, Di Carli MF, Blankstein R (2016) Presence of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Among Patients With Suspected Cardiac Sarcoidosis Is Associated With Adverse Cardiovascular Prognosis: A Systematic Review and Meta-Analysis. Cardiovasc Diagn Ther 6(1):50PubMedPubMedCentral

34.

Kandolin R, Lehtonen J, Kupari M (2011) Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 4:303–309PubMed

35.

Patel MR, Cawley PJ, Heitner JF et al (2009) Detection of myocardial damage in patients with sarcoidosis. Circulation 120:1979–1977

36.

Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G (2017) Nagel ET1 and T2 mapping in recognition of early cardiac involvement in systemic Sarcoidosis. Radiology 285:63–72PubMed

37.

Wicks EC, Menezes LJ, Barnes A, Mohiddin SA, Sekhri N, Porter JC, Booth HL, Garrett E, Patel RS, Pavlou M, Groves AM (2018) Elliott PM Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 19:757–767PubMed

38.

Viles-Gonzalez JF, Pastori L, Fischer A, Wisnivesky JP, Goldman MG, Mehta D (2013) Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest 143(4):1085–1090PubMed

39.

Soejima K, Yada H (2009) The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Eletrophysiol 20:578–583

40.

Schuller JL, Olson MD, Zipse MM (2011) Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol 22:1243–1248PubMed

41.

Das MK, Kahn B, Jacob S, Kumar A, Mahenthiran J (2006) Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation 113:2495–2501PubMed

42.

Burstow DJ, Tajik AJ, Bailey KR et al (1989) Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 63:478–482PubMed

43.

Fahy GJ, Marwick T, McCreery CJ et al (1996) Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 109:62–66PubMed

44.

Schulz-Menger J, Wassmuth R, Abdel-Aty H et al (2006) Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart 92:399–400PubMedPubMedCentral

45.

Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H, Amaki M, Kanzaki H, Okamura H, Kamakura S, Shimizu W, Anzai T, Kitakaze M (2014) Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100(15):1165–1172PubMed

46.

Smedema JP, Snoep G, van Kroonenburgh MP et al (2005) Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45:1683–1690PubMed

47.

Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M, Prasad S, Koulouris N, Sfikakis P, Wells A, Gialafos E (2017) Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac Sarcoidosis. JACC Cardiovasc Imaging 10(12):1437–1447PubMed

48.

Crouser ED, Ruden E, Julian MW, Raman SV et al (2016) Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis. J Investig Med 64:1148–1150PubMed

49.

Nazarian S, Hansford R, Rahsepar AA, Weltin V, McVeigh D, Gucuk Ipek E, Kwan A, Berger RD, Calkins H, Lardo AC, Kraut MA, Kamel IR, Zimmerman SL, Halperin HR et al (2017) Safety of magnetic resonance imaging in patients with cardiac devices. N Engl J Med 377:2555–2564PubMedPubMedCentral

50.

Koiwa HH, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M (2010) Images in cardiovascular medicine: imaging of cardiac sarcoid lesions using fasting cardiac 18F-fluorodeoxyglucose positron emission tomography: an autopsy case. Circulation 122:535PubMed

51.

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, Gulenchyn KY, Dekemp RA, Dasilva J, Birnie D, Wells GA, Beanlands RS (2012) The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53:241PubMed

52.

Betensky BP (2012) Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 9:884PubMed

53.

Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V, Palmisano A, Miller MA, Lala A, Chang HL, Sanz J, Contreras J, Narula J, Fuster V, Padilla M, Fayad ZA, Kovacic JC (2018) Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac Sarcoidosis. JACC Cardiovasc Imaging 11(1):94–107PubMed

54.

Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M et al (2014) Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 21(5):925–939. https://doi.org/10.1007/s12350-014-9901-9 CrossRefPubMed

55.

Nery PB, Beanlands RS, Nair GM, Green M, Yang J, McArdle BA et al (2014) Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 25(8):875–881. https://doi.org/10.1111/jce.12401 CrossRefPubMed

56.

Danwade TA, Devidutta S, Shelke AB, Saggu DK, Yalagudri SD, Sridevi C et al (2018) Prognostic value of fluorine-18 fluoro-2-deoxyglucose positron emission computed tomography in patients with unexplained atrioventricular block. Heart Rhythm. 15(2):234–239. https://doi.org/10.1016/j.hrthm.2017.10.025 CrossRefPubMed

57.

Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M, Central Japan Heart Study Group (2001) Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88(9):1006–1010PubMed

58.

Nensa F, Bamberg F, Rischpler C, Menezes L, Poeppel TD, la Fougère C, Beitzke D, Rasul S, Loewe C, Nikolaou K, Bucerius J, Kjaer A, Gutberlet M, Prakken NH, Vliegenthart R, Slart RHJA, Nekolla SG, Lassen ML, Pichler BJ, Schlosser T, Jacquier A, Quick HH, Schäfers M, Hacker M (2018) Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM). Eur Radiol 28(10):4086PubMedPubMedCentral

59.

Ardehali H, Howard DL, Hariri A et al (2005) A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 150:459–463PubMed

60.

Cooper LT, Baughman KL, Feldman AM et al (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 50:1914–1931PubMed

61.

Honda Y, Nagai T, Ikeda Y et al (2016) Myocardial immunocompetent cells and macrophage phenotypes as histopathological surrogates for diagnosis of cardiac sarcoidosis in Japanese. J Am Heart Assoc 5:e004019. https://doi.org/10.1161/JAHA.116.004019 CrossRefPubMedPubMedCentral

62.

Date T, Shinozaki T, Yamakawa M et al (2007) Elevated plasma brain natriuretic peptide level in cardiac sarcoidosis patients with preserved ejection fraction. Cardiology 107:277–280PubMed

63.

Yasutake H, Seino Y, Kashiwagi M, Honma H, Matsuzaki T, Takano T (2005) Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 102:259–268PubMed

64.

Statement on sarcoidosis (1999) Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160:736–755

65.

Grutters JC, van den Bosch JM (2006) Corticosteroid treatment in sarcoidosis. Eur Respir J 28:627–636PubMed

66.

Chiu CZ, Nakatani S, Zhang G et al (2005) Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 95:143–146PubMed

67.

Banba K, Kusano KF, Nakamuro K et al (2007) Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 4:1292–1299PubMed

68.

Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H (2003) Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 20(2):133–137PubMed

69.

Baughman RP, Grutters JC (2015) New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(15)00199-X CrossRef

70.

Epstein AE, Dimarco JP, Ellenbogen KA et al (2008) ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm 5:934–955PubMed

71.

Gutman SJ, Costello BT, Papapostolou S, Voskoboinik A, Iles L, Ja J, Hare JL, Ellims A, Kistler PM, Marwick TH, Taylor AJ et al (2019) Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart J 40:542–550PubMed

72.

Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF, Rosen SD, Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR, Cleland JGF, Cook SA, Pennell DJ, Prasad SK et al (2017) Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 135:2106–2115PubMedPubMedCentral

73.

Aizer A, Stern EH, Gomes JA et al (2005) Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 96:276–282PubMed

74.

Mehta D, Mori N, Goldbarg S et al (2011) Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 4:43–48PubMed

75.

Jefic D, Joel B, Good E et al (2009) Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 6:189–195PubMed

76.

Yodogawa K, Seino Y, Ohara T et al (2011) Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac Sarcoidosis. Ann Noninvasive Electrocardiol 16:140–147PubMedPubMedCentral

77.

Skowasch D, Ringquist S, Nickenig G, Andrié R (2018) Management of sudden cardiac death in cadiac sarcoidosis using the wearable cardioverter defibrilator. PLoS ONE 13(3):e194496PubMedPubMedCentral

78.

Oni AA, Hershberger RE, Norman DJ et al (1992) Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant 11:367–369PubMed

Titel: Diagnostik und Therapie der kardialen Sarkoidose
Konsensuspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) und Deutschen Gesellschaft für Kardiologie – Herz und Kreislaufforschung (DGK)
verfasst von: D. Skowasch
F. Gaertner
N. Marx
B. Meder
J. Müller-Quernheim
M. Pfeifer
J. W. Schrickel
A. Yilmaz
Prof. Dr. med. C. Grohé
Publikationsdatum: 20.12.2019
Verlag: Springer Medizin
Schlagwörter: Herzrhythmusstörungen
Ventrikuläre Tachykardien
Kardiomyopathie
Herzrhythmusstörungen
Sarkoidose
Sarkoidose
Erschienen in: Die Kardiologie / Ausgabe 1/2020
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-019-00359-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diagnostik und Therapie der kardialen Sarkoidose

Konsensuspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) und Deutschen Gesellschaft für Kardiologie – Herz und Kreislaufforschung (DGK)

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Berücksichtigung QTc-verlängerndes Potenzial: „Vor Einleitung einer Therapie mit Antibiotika, Antipsychotika, Antiarrhythmika soll die Gefahr einer klinisch relevanten QTc-Verlängerung geprüft werden“

Warnung vor Interaktionen – ASS + NSAR bei Patienten mit KHK/pAVK

Update Reanimation bei Herzstillstand – von Laienreanimation bis Kühlung

Medikamentöse Kontrolle kardiovaskulärer Risikofaktoren bei HIV-Patienten unter ART Therapie

CME: Kardiovaskuläre Nebenwirkungen moderner Tumortherapien – so schaffen Sie den Spagat

Klug entscheiden

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin